Few areas of medicine have undergone greater change during the past 50 years than infectious diseases. The optimism and clinical confidence associated with the development of antimicrobial agents from the 1940s onwards has been tempered by the emergence of new diseases, such as AIDS and infections associated with transplantation and cancer therapy, and by the widespread development of antibiotic resistance. Despite many advances, infectious diseases continue to account for about a quarter of all deaths worldwide1 (Box 1). Furthermore, a security dimension has emerged. A recent report on The global infectious disease threat and its implications for the United States from the US Central Intelligence Agency (CIA) analysed this "non-traditional threat": The dramatic increase in drug-resistant microbes, combined with the lag in development of new antibiotics, the rise of megacities with severe health care deficiencies, environmental degradation, and the growing ease and frequency of cross-border movements of people and produce have greatly facilitated the spread of infectious diseases.2
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 Infectious Diseases Department, Austin and Repatriation Medical Centre, Heidelberg, VIC.
- 2 Infectious Diseases and Microbiology Department, Alfred Hospital, Prahran, VIC.
- 1. World Health Organization. WHO report on infectious diseases. Removing obstacles to healthy development. Geneva: World Health Organization, 1999. WHO/CDS/99.1. Available at <http://www.who.int/infectious-disease-report/pages/graph1.html> Accessed Jan 2002.
- 2. Central Intelligence Agency (CIA). The global infectious disease threat and its implications for the United States. <http://www.odci.gov/cia/reports/nie/report/nie99-17d.html> Accessed Jan 2002.
- 3. National Health and Medical Research Council. How to use the evidence: assessment and application of scientific evidence. Handbook series on preparing clinical practice guidelines. Canberra: NHMRC, 2000: 8. Available at <http://www.nhmrc.gov.au/publications/synopses/cp65syn.htm> Sighted Jan 2002.
- 4. Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. 5th ed. New York: Churchill Livingstone, 2000.
- 5. McManus P, Hammond ML, Whicker SD, et al. Antibiotic use in the Australian community, 1990–1995. Med J Aust 1997; 167: 124-127. <eMJA full text>
- 6. Commonwealth Department of Health and Aged Care. National summit on antibiotic resistance. CIJIG Communique 2001; 1: 1-10.
- 7. WHO global strategy for containment of antimicrobial resistance. Geneva: World Health Organization, 2001.
- 8. WHO report on infectious diseases 2000: overcoming antimicrobial resistance. Geneva: World Health Organization, 2000. <www.who.int/infectious-disease-report/2000> Accessed Jan 2002.
- 9. Victorian Drug Usage Evaluation Group. Statewide evaluation of ceftriaxone and cefotaxime usage in Victorian hospitals. Report to the Victorian Drug Usage Advisory Committee and the Victorian Standing Committee on Infection Control. Melbourne: Victorian Drug Usage Evaluation Group, Aug 2000.
- 10. Robertson MB, Dartnell JG, Korman TM, and the Victorian Drug Usage Evaluation Group. Vancomycin and teicoplanin use in Victorian hospitals. Med J Aust 1999; 171: 127-131.